Denna buys TEVA 60.06: This is not the only recent acquisition that Teva has carried out to expand its generic drug business.

The company will also be using this combination of cash and credit to fund acquisition of portfolio of products and companies, assets, intellectual property, and pharmaceutical patents in Latin America and Europe. Teva announced that it will be using a combination of cash on hand as well as credit financing to fund the said acquisition. In addition, Rimsa also comes with a well-diversified and established portfolio of drugs, with a strong drug pipeline which is bound to be a valuable addition for Teva moving forward. Rimsa, with its large presence in emerging markets of Mexico and Latin America, provides a significant growth opportunity for Teva to become a leading drug-maker in Mexico. The acquisition of Rimsa is a smart decision by Teva at this point.


Glayds:
Its oncology portfolio comprises Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio.

Marin:
Its main respiratory medications contain ProAir Duoresp, QVAR and hydrofluoroalkane Spiromax.

Shantae:
This represents a $1.36 dividend on an annualized basis and a yield of 2.32%. The ex-dividend date of this dividend was Tuesday, August 18th.

Madeline:
Investors of record on Thursday, August 20th were issued a dividend of $0.34 per share.

Harriette:
Analysts anticipate that Teva Pharmaceutical Industries will post $5.32 earnings per share for the current fiscal year.

Lang:
Seven investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock.

Tamekia:
Finally, HSBC began coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, June 25th.

Vicenta:
Commodity prices have been heading lower for more than four years, being the worst performing asset class of 2015 with more losses in cyclical commodities.

Benita:
Learn about the top five energy companies to buy and hold.

Mandy:
Rimsa seems like it will be a good fit for the company, expanding its global footprint across a market with room to grow.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)
//stockhand.net/us/?q=nyse%3Ateva&id=693727